Patents by Inventor Wenyang HOU

Wenyang HOU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BINDING AGENTS TARGETING TROP2-EXPRESSING TUMOR CELLS
    Publication number: 20240360242
    Abstract: The present disclosure generally relates to binding agents, such as antibodies and antigen binding fragments thereof, that are capable of binding to trophoblast cell surface antigen-2 (TROP2). Also disclosed herein are binding agents that are capable of targeting TROP2-expressing tumor cells and their use for the treatment of cancer. Single domain antibodies that specifically binds to amino acid residues of the extracellular domain of TROP2 are provided.
    Type: Application
    Filed: March 28, 2024
    Publication date: October 31, 2024
    Inventors: Wenyang HOU, Shugang YAO, Luis DA CRUZ, David S. YOUNG
  • BINDING AGENTS TARGETING TROP2-EXPRESSING TUMOR CELLS
    Publication number: 20240327537
    Abstract: The present disclosure generally relates to binding agents, such as antibodies and antigen binding fragments thereof, that are capable of binding to trophoblast cell surface antigen-2 (TROP2). Also disclosed herein are binding agents that are capable of targeting TROP2-expressing tumor cells and their use for the treatment of cancer. Single domain antibodies that specifically binds to amino acid residues of the extracellular domain of TROP2 are provided.
    Type: Application
    Filed: May 14, 2024
    Publication date: October 3, 2024
    Inventors: Wenyang HOU, Shugang YAO, Luis DA CRUZ, David S. YOUNG
  • BINDING AGENTS TARGETING TROP2-EXPRESSING TUMOR CELLS
    Publication number: 20240317886
    Abstract: The present disclosure generally relates to binding agents, such as antibodies and antigen binding fragments thereof, that are capable of binding to trophoblast cell surface antigen-2 (TROP2). Also disclosed herein are binding agents that are capable of targeting TROP2-expressing tumor cells and their use for the treatment of cancer. Single domain antibodies that specifically binds to amino acid residues of the extracellular domain of TROP2 are provided.
    Type: Application
    Filed: May 14, 2024
    Publication date: September 26, 2024
    Inventors: Wenyang HOU, Shugang YAO, Luis DA CRUZ, David S. YOUNG
  • BINDING AGENTS TARGETING TROP2-EXPRESSING TUMOR CELLS
    Publication number: 20240317887
    Abstract: The present disclosure generally relates to binding agents, such as antibodies and antigen binding fragments thereof, that are capable of binding to trophoblast cell surface antigen-2 (TROP2). Also disclosed herein are binding agents that are capable of targeting TROP2-expressing tumor cells and their use for the treatment of cancer. Single domain antibodies that specifically binds to amino acid residues of the extracellular domain of TROP2 are provided.
    Type: Application
    Filed: May 14, 2024
    Publication date: September 26, 2024
    Inventors: Wenyang HOU, Shugang YAO, Luis DA CRUZ, David S. YOUNG
  • BINDING AGENTS TARGETING TUMORS AND/OR IMMUNE CELLS
    Publication number: 20240166739
    Abstract: The present disclosure generally relates to binding agents that are capable of targeting tumor cells and/or immune cells. The binding agents of the present disclosure comprise one or more antigen binding domains of heavy chain antibodies (HcAb) which are capable of binding to DR2, to PD-1 and/or to CD47. The binding agents of the present disclosure may be in the form of monomers or multimers and may be monospecific or multispecific.
    Type: Application
    Filed: March 25, 2022
    Publication date: May 23, 2024
    Applicant: KisoJi Biotechnology Inc.
    Inventors: Shugang YAO, Richard WARGACHUCK, Wenyang HOU, Luis DA CRUZ, David S. YOUNG
  • TRANSGENIC ANIMALS EXPRESSING HEAVY CHAIN ANTIBODIES
    Publication number: 20230270086
    Abstract: The present disclosure generally relates to transgenic animals comprising germline modifications at an immunoglobulin heavy chain (IgH) locus for expressing heavy chain antibodies (HCAbs) as well as nucleic acid constructs, cells and methods for generating same. The present disclosure also relates to binding agents comprising sequences derived from the heavy chain antibodies produced by the transgenic animals.
    Type: Application
    Filed: July 12, 2021
    Publication date: August 31, 2023
    Inventors: Wenyang HOU, Xin LI, Luis DA CRUZ, Ashwani GUPTA, David S. YOUNG